

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Modafinil**

**INITIATION – Narcolepsy**

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more

and

- ☐ The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods

or

- ☐ The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations

and

- ☐ An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects

or

- ☐ Methylphenidate and dexamphetamine are contraindicated

or

- ☐ Patient meets the Hospital Restriction criteria for methylphenidate hydrochloride for narcolepsy

and

- ☐ Patient is unable to access methylphenidate hydrochloride presentations due to an out of stock (see note)

Note: Criterion 2 is to permit short-term funding to cover an out-of-stock of methylphenidate hydrochloride.

I confirm that the above details are correct:

Signed: ..... Date: .....